Epigenetic factors play a significant role in how the immune system responds to vaccines, influencing gene expression without altering the DNA sequence itself. Environmental factors, age, and individual genetic predispositions can all impact epigenetic modifications that regulate immune responses. In vaccinology, understanding these factors is critical because they can influence how long-lasting or effective a vaccine’s protection will be. For instance, epigenetic changes may affect the function of immune cells, like T-cells or B-cells, which are responsible for creating immune memory. Researchers are exploring how epigenetic modifications can be leveraged to enhance vaccine efficacy, particularly in vulnerable populations, such as the elderly or individuals with chronic conditions. This emerging area of study could lead to more personalized vaccines that can train the immune system more effectively, improving overall vaccine responses across diverse populations and increasing immunity to a variety of pathogens.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States